ClinicalTrials.gg
CompletedNCT00645424Updated Feb 18, 2021

A Study To Evaluate The Safety And Efficacy Of Atorvastatin In Patients With Diabetes And High Cholesterol

A Phase 4 interventional study of atorvastatin and atorvastatin in Hyperlipidemias, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 5 sites in Taiwan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 37 studies testing atorvastatin in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. Atorvastatin · Hyperlipidemias.

Enrollment
16th of 37
155 · median 99
Started
2003
with 3 others
Phase 4
10 of 37
none open now
Registered
15th of 37
by date
Lead sponsor
4 of 37
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 37 studies testing atorvastatin in Hyperlipidemias, this one is the 16th largest by enrollment, is one of 4 that started in 2003, is one of 10 in phase 4, and was the 15th registered.

Hyperlipidemias

863 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

None of the 37 studies testing atorvastatin in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Hyperlipidemias studies recruiting now, 26 (39%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 37 studies testing atorvastatin in Hyperlipidemias as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of atorvastatin for the treatment of Taiwanese patients with diabetes and high cholesterol.

03

Conditions studied

  • Hyperlipidemias

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult Taiwanese outpatients with type 2 diabetes mellitus and high cholesterol
  • levels of ≤10%, LDL-C levels of ≥130 mg/dL, and serum triglyceride levels of \<400 mg/dL

Exclusion criteria

Exclusion Criteria:

  • Type I diabetes mellitus
  • Secondary causes of high cholesterol
  • Elevated liver enzymes
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
155 participants (actual)

Study arms

  • Experimental
    Arm A

    Drug: atorvastatin

  • Experimental
    Arm B

    Drug: atorvastatin

  • Experimental
    Arm C

    Drug: atorvastatin

Interventions

  • Atorvastatin calcium tablets 10 mg orally once daily in the evening for 12 weeks

  • Atorvastatin calcium tablets 20 mg orally once daily in the evening for 12 weeks

  • Atorvastatin calcium tablets 40 mg orally once daily in the evening for 12 weeks

06

What researchers measure

Primary outcomes

  1. Percentage change in LDL-C levels from baseline to Week 12

    Time frame: Week 12

  2. Percentage of subjects with low-density lipoprotein cholesterol (LDL-C) levels of <100 mg/dL (LDL-C responders) at Week 12

    Time frame: Week 12

Secondary outcomes

  1. Percentage change from baseline in TC, high-density lipoprotein cholesterol, triglycerides, and high sensitivity C-reactive protein at Weeks 4, 8, and 12

    Time frame: Weeks 4, 8, and 12

  2. Adverse events at Weeks 4, 8, and 12

    Time frame: Baseline and at Weeks 4, 8, and 12

  3. Clinical laboratory changes at Weeks 4, 8, and 12

    Time frame: Screening and at Weeks 4, 8, and 12

  4. Vital signs at Weeks 4, 8, and 12

    Time frame: Screening and at Weeks 4, 8, and 12

  5. Percentage change in LDL-C levels from baseline at Weeks 4 and 8

    Time frame: Weeks 4 and 8

  6. Percentage of LDL-C responders at Weeks 4 and 8

    Time frame: Weeks 4 and 8

  7. Percentage of subjects with total cholesterol (TC) levels of <160 mg/dL (TC responders) at Weeks 4, 8, and 12

    Time frame: Weeks 4, 8, and 12

07

Study locations

5 sites
  • Pfizer Investigational Site
    Kaohsiung Hsien, Taiwan
  • Pfizer Investigational Site
    Kaohsiung, Taiwan
  • Pfizer Investigational Site
    Taichung, Taiwan
  • Pfizer Investigational Site
    Taipei, Taiwan
  • Pfizer Investigational Site
    Taoyuan Hsien, Taiwan
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2003 and a completion of Oct 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2008
First posted
Mar 27, 2008
Start
Dec 2003
CompletionActual
Oct 2004
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00645424
Responsible party
Sponsor
First posted
Mar 27, 2008
Start date
Dec 2003
Completion
Oct 2004
Last update
Feb 18, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion